Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
Frequently asked questions
What sector does Andros Pharmaceuticals Co.,Ltd (6917) operate in?
Andros Pharmaceuticals Co.,Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is Andros Pharmaceuticals Co.,Ltd (6917) current stock price?
As of the latest data, Andros Pharmaceuticals Co.,Ltd stock price is NT$32.10, with a previous close of NT$32.10.
What is Andros Pharmaceuticals Co.,Ltd (6917) current market capitalization?
Andros Pharmaceuticals Co.,Ltd market cap is approximately 1.77 billion.
What is Andros Pharmaceuticals Co.,Ltd (6917) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.16.
Does Andros Pharmaceuticals Co.,Ltd (6917) pay dividends?
No. Andros Pharmaceuticals Co.,Ltd does not pay a dividend.
What is Andros Pharmaceuticals Co.,Ltd (6917) beta (volatility) score?
Andros Pharmaceuticals Co.,Ltd has a beta of 0.322, indicating lower volatility than the overall market.
